Wyeth diet drugs: slim financial pickings

home   >   blogdigger

Wyeth has suffered a loss in its fourth quarter, due in part to charges relating to its 'fen-phen' diet drug litigation. However, it has reported strong full-year growth for a number of key products, including Effexor, Protonix, Prevnar, Enbrel and Zosyn.

- link to Wyeth diet drugs: slim financial pickings -
Last update: 05/26/2005

Recommended Reading

    Celecoxib Approved for Familial Adenomatous Polyposis.(Brief Article)(Statistical Data Included) : An article from: Family Practice News
    Neuropathic Pain Calls for Adjuvant Agent. : An article from: Family Practice News
    Clopidogrel plus aspirin cut ischemic events 27%. (Dual Therapy Post Angioplasty).(Plavix) : An article from: Family Practice News
    Leukotriene Users Need Fewer Oral Steroid Rescues. : An article from: Internal Medicine News
    Supratherapeutic dosing of olanzapine may help refractory schizophrenia. (Improved Social Functioning). : An article from: Clinical Psychiatry News
    ACTOS DE FE : Meditaciones Diarias Para Mejorar el Espiritu
    Mxico expulsa a extranjeros. (gobierno rechaza a activistas que participan en actos polticos relacionados al conlicto armado de Chiapas; incluye artcu ... es related article) : An article from: Semana
    Two more drugs approved for social anxiety. (Sertraline, Venlafaxine). : An article from: Internal Medicine News